These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10169390)

  • 1. Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial.
    Nord E; Wisløff F; Hjorth M; Westin J
    Pharmacoeconomics; 1997 Jul; 12(1):89-103. PubMed ID: 10169390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
    Ann Intern Med; 1996 Jan; 124(2):212-22. PubMed ID: 8533996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma.
    Gulbrandsen N; Wisløff F; Nord E; Lenhoff S; Hjorth M; Westin J;
    Eur J Haematol; 2001 May; 66(5):328-36. PubMed ID: 11422413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group.
    Wisløff F; Hjorth M; Kaasa S; Westin J
    Br J Haematol; 1996 Aug; 94(2):324-32. PubMed ID: 8759893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study.
    Cooper MR; Dear K; McIntyre OR; Ozer H; Ellerton J; Canellos G; Bernhardt B; Duggan D; Faragher D; Schiffer C
    J Clin Oncol; 1993 Jan; 11(1):155-60. PubMed ID: 8418228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatments for newly diagnosed multiple myeloma: analysis of survival data and cost-effectiveness evaluation.
    Trippoli S; Messori A; Becagli P; Alterini R; Tendi E
    Oncol Rep; 1998; 5(6):1475-82. PubMed ID: 9769391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon alfa-2b/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial.
    Cooper MR; Fefer A; Thompson J; Case DC; Kempf R; Sacher R; Neefe J; Bickers J; Scarffe JH; Spiegel RJ
    Invest New Drugs; 1987; 5 Suppl():S41-6. PubMed ID: 3597002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of the clinical studies of alpha-interferon in the management of multiple myeloma.
    Cooper MR
    Semin Oncol; 1991 Oct; 18(5 Suppl 7):18-29. PubMed ID: 1948125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
    Usmani SZ; Cavenagh JD; Belch AR; Hulin C; Basu S; White D; Nooka A; Ervin-Haynes A; Yiu W; Nagarwala Y; Berger A; Pelligra CG; Guo S; Binder G; Gibson CJ; Facon T
    J Med Econ; 2016; 19(3):243-58. PubMed ID: 26517601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related quality of life and patients' perceptions in interferon-treated multiple myeloma patients. Nordic Myeloma Study Group.
    Wisløff F; Gulbrandsen N
    Acta Oncol; 2000; 39(7):809-13. PubMed ID: 11145438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
    Sullivan SD; Craxi A; Alberti A; Giuliani G; De Carli C; Wintfeld N; Patel KK; Green J
    Pharmacoeconomics; 2004; 22(4):257-65. PubMed ID: 14974875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.
    Browman GP; Bergsagel D; Sicheri D; O'Reilly S; Wilson KS; Rubin S; Belch A; Shustik C; Barr R; Walker I
    J Clin Oncol; 1995 Sep; 13(9):2354-60. PubMed ID: 7666094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon therapy during the plateau phase of multiple myeloma: an update of a Swedish multicenter study.
    Westin J
    Semin Oncol; 1991 Oct; 18(5 Suppl 7):37-40. PubMed ID: 1948128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma.
    Zeng X; Liu Q; Peng L; Peng Y; Yi L; Luo X; Li S; Wan X; Tan C
    Adv Ther; 2021 May; 38(5):2379-2390. PubMed ID: 33770365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group.
    Wisløff F; Eika S; Hippe E; Hjorth M; Holmberg E; Kaasa S; Palva I; Westin J
    Br J Haematol; 1996 Mar; 92(3):604-13. PubMed ID: 8616024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
    Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
    Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic options in the treatment of multiple myeloma: pharmacoeconomic and quality-of-life considerations.
    Wisløff F; Gulbrandsen N; Nord E
    Pharmacoeconomics; 1999 Oct; 16(4):329-41. PubMed ID: 10623362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
    Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
    J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon therapy during the plateau phase of multiple myeloma: an update of the Swedish study.
    Westin J; Cortelezzi A; Hjorth M; Rödjer S; Turesson I; Zador G
    Eur J Cancer; 1991; 27 Suppl 4():S45-8. PubMed ID: 1799477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.